Why Medical Weight Loss Works
GLP-1 Medications Address the Biology of Obesity
Obesity is a complex chronic disease with strong physiologic drivers — not simply a matter of willpower. GLP-1 receptor agonists like semaglutide and GLP-1/GIP dual agonists like tirzepatide address these biological drivers directly, reducing appetite signaling, slowing gastric emptying, improving insulin sensitivity, and producing sustained caloric deficit without chronic hunger. Indianapolis patients treated at MD Vitality Wellness Center with these medications typically report that food simply becomes less of an obsession — they feel full on less food and experience dramatically fewer cravings. When combined with behavior change and supportive therapies, the results are transformative.
GLP-1 medications reduce appetite through central and peripheral mechanisms
Slowed gastric emptying extends satiety between meals
Improved insulin sensitivity benefits metabolic health beyond weight loss
Semaglutide: average 10–15% body weight loss over 68 weeks
Tirzepatide: average 20–22% body weight loss in clinical trials
Both programs starting from $225/mo in Indianapolis
